News

Klaus Friedrich Rabe, MD, PhD, spoke at ATS about the mixed phase 3 AERIFY trial findings on itepekimab, an anti–IL-33 monoclonal antibody, in COPD.

At ATS, Klaus Friedrich Rabe, MD, PhD, discussed phase 3 data on itepekimab in former smokers with chronic obstructive pulmonary disease (COPD).

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover more of the upcoming news releases announced for ADA 2026.

Experts unpack new asthma/COPD biologics, eosinophil+FeNO targeting, twice-yearly depemokimab switching, and payer hurdles in 2026 care.

Deepak Bhatt, MD, MPH, MBA, discusses his recent presentation at the ASPC 2026 Virtual Imaging Symposium and how plaque imaging can change the MI landscape.

At ATS 2026, Vallerie McLaughlin, MD discusses ADVANCE OUTCOMES showing ralinepag reduced PAH clinical worsening risk by 55% in pretreated patients.

This interview at ATS highlights key takeaways regarding new phase 3 data on AD109 for obstructive sleep apnea (OSA).

Results from the phase 3 TETON-1 study presented at ATS 2026 showed inhaled treprostinil preserved lung function and reduced clinical worsening risk in IPF.

At ATS 2026, pooled phase 3 data showed mepolizumab reduced COPD exacerbations and hospitalizations in patients with blood eosinophil counts starting at 150 cells/µL.

This interview at ATS 2026 highlights notable findings on the once-nightly oral pill, AD109, in obstructive sleep apnea (OSA).

At ATS 2026, phase 3b ENCORE findings showed amikacin liposome inhalation suspension achieved high culture conversion rates in newly diagnosed MAC lung disease.

Kyle Staller, MD, MPH, explains new real-world data showing 41% of IBS-C patients change treatments at least once, with each switch driving higher HCRU and provider portal burden.

This potential new treatment option shows potential for patients living with obstructive sleep apnea.

Carel le Roux, PhD, MSC, discusses the investigative dual GLP-1/glucagon agonist’s weight loss efficacy in patients with obesity and overweight without T2D.

FDA granted priority review to asundexian for secondary prevention after non-cardioembolic ischemic stroke or TIA.

Periconception eosinophils may serve as a biomarker to identify asthma risk in gestation, according to Christian Cardillo, MD, who presented late-breaking data at ATS 2026.

As dermatology patients enter clinical visits with information from social media, online forums, and AI inquiries, clinicians are juggling new concerns.

This episode covers key trial results and presentations to keep an eye on as ADA 2026 approaches.

An expert describes his perspective on sequencing, APRIL inhibition, proteinuria endpoints, and long-term kidney preservation in IgA nephropathy.

In patients with COPD, heart rate measured during the 6-minute walk test were associated with greater hospital utilization, according to Andrew Truong-An Ho, MD, at ATS 2026.

At ATS 2026, Robert Wallis, MD, shared preliminary phase 2c data showing a novel 4-month pan-TB regimen containing sutezolid and N-acetylcysteine improved lung function recovery.

Phase 2 LANTIC trial data show corabotase maintained glabellar line improvement in 60.8% of patients at week 24 versus 36.7% for Dysport.

FDA approved baxdrostat as add-on therapy for adults with hypertension not controlled on other medications.

Maintenance extracorporeal photopheresis was associated with improved survival in lung transplant recipients with bronchiolitis obliterans syndrome, according to Alan Betensley, MD.

At ATS 2026, investigators reported that pediatric pulmonary rehabilitation improved exercise capacity and quality of life in chronic respiratory disease.

Adults with difficult-to-treat psoriasis due to overweight or obesity saw notable benefits to both with concomitant ixekizumab and tirzepatide.

A study presented at the ATS 2026 found the New York City Housing Authority’s Mold Busters program was associated with nearly 2800 fewer annual asthma-related ED visits.

Fechner discusses the 2-year data from an open-label extension of the CAHtalyst Pediatric study, maintaining substantial glucocorticoid dose lowering.